Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.49 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118340 | 0.94 | KEAP1 (0.59) | PTGS2HPGDRECQLKEAP1CA12 | |
| SCHEMBL10646367 | 0.92 | HPGD (0.57) | PTGS2HPGDRECQLKEAP1CA12 | |
| SCHEMBL3555520 | 0.84 | KDM4E (0.59) | PTGS2HPGDRECQLKEAP1KDM4E | |
| SCHEMBL31041151 | 0.84 | KIF11 (0.79) | KIF11HPGDKEAP1CA12CA1 | |
| SCHEMBL2040073 | 0.84 | KIF11 (0.61) | KIF11PIP4K2APIP4K2BALDH1A1SMN1; SMN2 | |
| SCHEMBL10417625 | 0.83 | HPGD (0.56) | PTGS2HPGDRECQLKEAP1KDM4E | |
| SCHEMBL5899945 | 0.82 | HPGD (0.64) | KIF11HPGDRECQLCA12CA1 | |
| Lithium SCHEMBL31041154 | 0.82 | KIF11 (0.76) | KIF11HPGDKEAP1CA12CA1 | |
| SCHEMBL13157249 | 0.82 | NPC1 (0.59) | PTGS2HPGDRECQLKEAP1KMT2A | |
| SCHEMBL3019804 | 0.82 | PTPN11 (0.50) | PTGS2HPGDRECQLKEAP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1539158-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KIF11 3986/4885PTGS2 960/4885HPGD 1033/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KIF11 3986/4885PTGS2 960/4885HPGD 1033/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | KIF11 4017/4885PTGS2 1337/4885HPGD 885/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KIF11 3986/4885PTGS2 960/4885HPGD 1033/4885 |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | KIF11 4151/4885PTGS2 3504/4885HPGD 3517/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KIF11 4009/4885PTGS2 1128/4885HPGD 763/4885 |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | LDLR, NR1H2, NR1H3 | KIF11 4200/4885PTGS2 2083/4885HPGD 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.